Table 1 Characteristics of included studies on BRCA in prospective studies

Cybulski et al. [8]

2498 (213 cases) BRCA1

569 (46 cases) BRCA2

✓

All cases prospectively ascertained

Kim et al. [37]

2737 (242 cases) BRCA1

756 (61 cases) BRCA2

✓-

0.49 (0.30–0.82)

(adolescent, BRCA1/2)

All cases prospectively ascertained

Ko et al. [22]

3920 BRCA1 or 2

(544 cases with BRCA1,

153 cases with BRCA 2)

✓ + 

1.28 (1.00–1.64)

(current, BRCA1/2)

1.34 (1.04–1.73)

(duration, BRCA1/2)

All cases prospectively ascertained

Schrijver et al. [38]

2276 (269 cases) BRCA1

1610 (157 cases) BRCA2

✓ + 

1.75 (1.03–2.97)

(HC, ever, BRCA2)

All cases prospectively ascertained

Kehm et al. [39]

659 (110 cases) BRCA1

526 (69 cases) BRCA2

✓-

0.41 (0.20–0.83)

(current, BRCA2)

All cases prospectively ascertained

Lecarpentier et al. [40] *

863 (332 cases) BRCA1

474 (167 cases) BRCA2

✓ + 

2.29 (1.07–4.89)

(MHT, duration, BRCA1/2)

✓ + −

5.46 (2.49–12.0)

(low, BRCA2)

0.56 (0.37–0.85)

(high, BRCA1)

0.48 (0.24–0.97)

(high, BRCA2)

Pijpe et al. [41]*

1026 (468 cases) BRCA1/2

✓−

0.63 (0.44–0.91)

(adult, BRCA1/2)

Qian et al. [42]*

14,676 (7360 cases) BRCA1

7912 (4091 cases) BRCA2

✓−

0.83 (0.76–0.90) (adolescent, BRCA1/2)

0.94 (0.90–0.98)

(current, BRCA1/2)

Brohet et al. [43]*

1181 (597 cases) BRCA1

412 (249 cases) BRCA2

✓ + 

1.47 (1.16–1.87)

(HC, ever, BRCA1/2)

Lecarpentier et al. [11]*

863 (332 cases) BRCA1

474 (163 cases) BRCA2

✓

✓